Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Skeletal Radiol ; 48(12): 1905-1914, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31154494

RESUMO

OBJECTIVE: To determine the image quality of fast spin echo (FSE) with mDixon relative to spectral attenuated inversion recovery (SPAIR) FSE sequences in musculoskeletal tumor imaging on a 1.5-T MRI system. MATERIALS AND METHODS: In a HIPAA-compliant prospective study, 265 patients requiring musculoskeletal tumor MRI scans were included. Patient consent was waived by the medical ethical committee. Two radiologists compared SPAIR and mDixon FSE water-only images in both T2- and T1-weighted gadolinium-enhanced (T1-Gd) sequences using a five-point scale (paired samples t test and visual grading characteristics curves (VGC)). Homogeneity of fat suppression, noise, contrast, several artifacts (motion, phase, edge blurring and water-fat swap) and subjective preference were evaluated. RESULTS: Readers did not have subjective preference for either sequence in 71% and 55% (reader 1 and 2, respectively). Scores for homogeneous fat suppression were significantly (p < 0.01) higher for mDixon (4.88 in T2 and 4.87 in T1-Gd) than for SPAIR (4.31 for T2 and 4.21 for T1-Gd). All VGC curves for homogeneity demonstrated preference for mDixon. In 57 individual mDixon cases, fat-suppression homogeneity was strikingly better (≥ 2 points higher), namely in areas with field heterogeneity. Average noise and contrast scores were slightly higher for mDixon, as were motion artifact scores for SPAIR (< 0.5 points difference). CONCLUSIONS: mDixon fat suppression was significantly more homogeneous than SPAIR on both T2 and T1-Gd FSE images in musculoskeletal tumor protocols. In areas of field inhomogeneity, mDixon outperforms SPAIR. SPAIR had slightly less motion artifacts than mDixon.


Assuntos
Neoplasias Ósseas/diagnóstico por imagem , Aumento da Imagem/métodos , Imageamento por Ressonância Magnética/métodos , Neoplasias Musculares/diagnóstico por imagem , Tecido Adiposo/diagnóstico por imagem , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Artefatos , Criança , Meios de Contraste , Feminino , Humanos , Masculino , Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos , Estudos Prospectivos
2.
Pediatr Blood Cancer ; 54(2): 216-21, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19890902

RESUMO

INTRODUCTION: Resection of pulmonary metastases has previously been reported to improve outcome in high-grade osteosarcoma (OS) patients. Factors influencing survival in OS patients with pulmonary metastases are important for clinical decision making. METHODS: All 88 OS patients with pulmonary metastases either at diagnosis or during follow-up treated at the Leiden University Medical Center between January 1, 1990 and January 1, 2008 under the age of 40 were included in this study, including 79 cases of conventional, 8 cases of telangiectatic and 1 case of small cell OS. RESULTS: In total, 56 of 88 patients with pulmonary metastases were treated by metastasectomy. Resectability of pulmonary metastases was the main prognostic factor. In patients with primary non-metastatic OS, a longer relapse free interval to pulmonary metastases was significantly associated with better survival (P = 0.02). Independent risk factors determining worse survival after metastasectomy in multivariate analysis were male sex (P = 0.05), higher number of pulmonary nodules (P = 0.03), and non-necrotic metastases (P = 0.04). Whether surgery for recurrent pulmonary metastases was performed did not influence survival. Histological subtype of the primary tumor, histological response in the primary tumor after neo-adjuvant chemotherapy, occurrence of local relapse, local resection or amputation of the primary tumor and age at diagnosis did not influence outcome. CONCLUSION: This cohort of patients with detailed follow-up data enabled us to identify important risk factors determining survival in OS patients with pulmonary metastases. We demonstrate that after repeated metastasectomies, a subset of patients can be cured.


Assuntos
Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/terapia , Osteossarcoma/secundário , Osteossarcoma/terapia , Adulto , Terapia Combinada , Feminino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/cirurgia , Masculino , Análise Multivariada , Neoplasias Primárias Múltiplas , Segunda Neoplasia Primária , Osteossarcoma/diagnóstico , Osteossarcoma/cirurgia , Prognóstico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Análise de Sobrevida
3.
AJR Am J Roentgenol ; 178(5): 1181-7, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11959728

RESUMO

OBJECTIVE: Our purpose was to evaluate prospectively whether MR imaging, including dynamic contrast-enhanced MR imaging, could be used to categorize peripheral vascular malformations and especially to identify venous malformations that do not need angiography for treatment. SUBJECTS AND METHODS: In this blinded prospective study, two observers independently correlated MR imaging findings of 27 patients having peripheral vascular malformations with those of diagnostic angiography and additional venography. MR diagnosis of the category, based on a combination of conventional and dynamic contrast-enhanced MR parameters, was compared with the angiographic diagnosis using gamma statistics. Sensitivity and specificity of conventional MR imaging and dynamic contrast-enhanced MR imaging in differentiating venous from nonvenous malformations were determined. RESULTS: Excellent agreement between the two observers in determining MR categories (gamma = 0.99) existed. Agreement between MR categories and angiographic categories was high for both observers (gamma = 0.97 and 0.92). Sensitivity of conventional MR imaging in differentiating venous and nonvenous malformations was 100%, whereas specificity was 24-33%. Specificity increased to 95% by adding dynamic contrast-enhanced MR imaging, but sensitivity decreased to 83%. CONCLUSION: Conventional and dynamic contrast-enhanced MR parameters can be used in combination to categorize vascular malformations. Dynamic contrast-enhanced MR imaging allows diagnosis of venous malformations with high specificity.


Assuntos
Meios de Contraste , Aumento da Imagem , Imageamento por Ressonância Magnética , Doenças Vasculares Periféricas/congênito , Doenças Vasculares Periféricas/diagnóstico , Flebografia , Veias/anormalidades , Veias/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Vasculares Periféricas/classificação , Estudos Prospectivos , Sensibilidade e Especificidade , Método Simples-Cego , Fatores de Tempo
4.
J Magn Reson Imaging ; 15(3): 302-7, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11891975

RESUMO

PURPOSE: To explore the potential of perfusion-corrected diffusion-weighted magnetic resonance imaging (MRI) in characterizing soft-tissue tumors. METHODS AND MATERIALS: Diffusion-weighted MRI was performed in 23 histologically proven soft-tissue masses using a diffusion-weighted spin-echo sequence with diffusion gradient strengths yielding five b-values (0-701 seconds/mm(2)). True diffusion coefficients and perfusion fractions were estimated and compared with apparent diffusion coefficients (ADCs). RESULTS: ADC values of all tumors, subcutaneous fat, and muscle were significantly higher than true diffusion coefficients, indicating a contribution of perfusion to the ADC. True diffusion coefficients of malignant tumors (1.08 x 10(-3) mm(2)/second) were significantly lower than those of benign masses (1.71 x 10(-3) mm(2)/second), whereas ADC values between these groups were not significantly different. CONCLUSION: Perfusion-corrected diffusion-weighted MRI has potential in differentiating benign from malignant soft-tissue masses.


Assuntos
Imageamento por Ressonância Magnética/métodos , Neoplasias de Tecidos Moles/diagnóstico , Adolescente , Adulto , Idoso , Criança , Diagnóstico Diferencial , Difusão , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Perfusão , Neoplasias de Tecidos Moles/patologia
5.
Eur Radiol ; 13(8): 1849-58, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12942285

RESUMO

The objective of this study was to evaluate whether dynamic contrast-enhanced MR imaging can determine tumor response and localize residual viable tumor after isolated limb perfusion (ILP) chemotherapy in soft tissue tumors. Twelve consecutive patients, with histologically proven high-grade soft tissue sarcoma, prospectively underwent non-enhanced MR and dynamic contrast-enhanced MR imaging before and after ILP. Tumor volume was measured on non-enhanced MR images. The temporal change of signal intensity in a region of interest on dynamic contrast-enhanced MR images was plotted against time. Start, pattern, and progression of enhancement were recorded. Histopathologic response was defined as complete response if no residual viable tumor was present, partial remission if <50% viable tumor was present, and no change if > or =50% viable tumor was present in the resection specimen. Resected specimens for correlation with histopathology were available for 10 patients; 5 patients had partial remission and 5 had no change. Volume measurements correctly predicted tumor response in 6 of 10 patients. Dynamic contrast-enhanced MR correctly predicted tumor response in 8 of 10 patients. Early rapidly progressive enhancement correlated histologically with residual viable tumor. Late and gradual, or absence of enhancement, was associated with necrosis, predominantly centrally located, or granulation tissue. These preliminary results show that dynamic contrast-enhanced MR imaging offers potential for non-invasive monitoring of response to isolated limb perfusion in soft tissue sarcomas due to identification of residual areas of viable tumor and subsequently may provide clinically useful information with regards to timing and planning of additional surgery. Further prospective studies in a larger patient population is warranted.


Assuntos
Antineoplásicos/uso terapêutico , Quimioterapia do Câncer por Perfusão Regional , Imageamento por Ressonância Magnética/métodos , Melfalan/administração & dosagem , Sarcoma/tratamento farmacológico , Fator de Necrose Tumoral alfa/administração & dosagem , Antineoplásicos/administração & dosagem , Meios de Contraste , Extremidades , Feminino , Gadolínio DTPA , Humanos , Masculino , Melfalan/uso terapêutico , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa